Vunakizumab clinical trials
Also written SHR-1314.
How each study uses vunakizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the vunakizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2025 (5)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 17 · Other 2
Suzhou Suncadia Biopharmaceuticals Co., Ltd. (9) · Jiangsu HengRui Medicine Co., Ltd. (7) · Atridia Pty Ltd. (1) · Fujian Cancer Hospital (1) · Chinese SLE Treatment And Research Group (1)
Often tested with
Tested in the same studies.
Adebrelimab (1) · Antineoplastic Agents (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test vunakizumab.
- Nov 2026Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus ErythematosusPhase 1 · Chinese SLE Treatment And Research Group
- Mar 2027Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque PsoriasisPhase 4 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Studies
Open first, then newest update. How each study uses vunakizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 19
- A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and ChemotherapyNot yet recruitingPhase 2Fujian Cancer HospitalNCT07069270Written as Vunakizumab (IL-17A inhibitor)
- Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus ErythematosusRecruitingPhase 1Chinese SLE Treatment And Research GroupNCT06881290Written as Vunakizumab (IL-17A inhibitor)
- A Trial of SHR-1314 Injection in Adult Patients With Active Non-radiographic Axial SpondyloarthritisRecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06860750Written as SHR-1314 Injection
- The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque PsoriasisNot yet recruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06833307Written as SHR-1314
- Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque PsoriasisNot yet recruitingPhase 4Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06779097Written as Vunakizumab (IL-17A inhibitor)
- A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic ArthritisActive, not recruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06640257Written as SHR-1314 injection
- Efficacy and Safety of SHR-1314 by Subcutaneous Injection in Active Moderate to Severe Graves' Orbitopathy PatientsTerminatedPhase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT05394857Written as SHR-1314
- Study of the Effectiveness and Safety of SHR-1314 for Psoriatic ArthritisCompletedPhase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT05055934Written as SHR-1314 injection
- A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications DevicesCompletedPhase 1Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06182384Written as SHR-1314
- Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing SpondylitisCompletedPhase 2/3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT04840485Written as SHR-1314
- Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque PsoriasisCompletedPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT03463187Written as SHR-1314
- A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus NephritisStatus unknownPhase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT04924296Written as SHR-1314
- Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque PsoriasisStatus unknownPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT04839016Written as SHR-1314
- Safety, Tolerability and PK of SHR1314 in axSpACompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT03704428Written as SHR-1314
- A Bioequivalence Study to Compare Two Formulations of SHR-1314 After Subcutaneous Injection in Healthy SubjectsStatus unknownPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04527484Written as SHR-1314
- A Study to Compare Pharmacokinetic and Safety Profiles of Different Formulations of SHR-1314 After Subcutaneous Injection in Healthy SubjectsStatus unknownPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04326881Written as SHR-1314
- A Clinical Study of SHR-1314 Injection in the Treatment of Moderate to Severe Plaque Psoriasis in AdultsSuspendedPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT04121143Written as IL-17A Antagonist
- A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque PsoriasisStatus unknownPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT03710681Written as SHR-1314
- A Study of SHR-1314 in Healthy SubjectsCompletedPhase 1Atridia Pty Ltd.NCT02934412Written as SHR-1314
Codes
What other systems call vunakizumab · ClinicalTrials.gg INT018546
- UNII (FDA) Y4U029R8MSVUNAKIZUMABOne source FDA
- NCI Thesaurus C152923VunakizumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Y4U029R8MS | VUNAKIZUMAB | One source FDA |
| NCI Thesaurus | C152923 | Vunakizumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.